BioLife Solutions (BLFS) Valuation After Strong Q3 Beat, Guidance Raise, and New Biopreservation Center Opening

Simply Wall St.12-08

BioLife Solutions (BLFS) has given investors plenty to chew on after Q3, with an earnings beat, stronger revenue guidance for its cell processing platform, and a new biopreservation center opening in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589805638?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","is_english":true,"pubTime":"2025-12-08 01:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589805638","market":"hk","top_or_hot":-1,"title":"BioLife Solutions (BLFS) Valuation After Strong Q3 Beat, Guidance Raise, and New Biopreservation Center Opening","media":"Simply Wall St.","content":"<div>\n<p>BioLife Solutions (BLFS) has given investors plenty to chew on after Q3, with an earnings beat, stronger revenue guidance for its cell processing platform, and a new biopreservation center opening in ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blfs/biolife-solutions/news/biolife-solutions-blfs-valuation-after-strong-q3-beat-guidan\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioLife Solutions (BLFS) Valuation After Strong Q3 Beat, Guidance Raise, and New Biopreservation Center Opening</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioLife Solutions (BLFS) Valuation After Strong Q3 Beat, Guidance Raise, and New Biopreservation Center Opening\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-08 01:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blfs/biolife-solutions/news/biolife-solutions-blfs-valuation-after-strong-q3-beat-guidan><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioLife Solutions (BLFS) has given investors plenty to chew on after Q3, with an earnings beat, stronger revenue guidance for its cell processing platform, and a new biopreservation center opening in ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blfs/biolife-solutions/news/biolife-solutions-blfs-valuation-after-strong-q3-beat-guidan\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLFS","symbol_name":"BioLife Solutions Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blfs/biolife-solutions/news/biolife-solutions-blfs-valuation-after-strong-q3-beat-guidan","article_id":"2589805638","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blfs/biolife-solutions/news/biolife-solutions-blfs-valuation-after-strong-q3-beat-guidan","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589805638","pubTimestamp":1765127592,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BioLife Solutions (BLFS) has given investors plenty to chew on after Q3, with an earnings beat, stronger revenue guidance for its cell processing platform, and a new biopreservation center opening in Bothell.\nSee our latest analysis for BioLife Solutions.\nEven with the upbeat Q3 and the new biopreservation center signaling a long runway for its CGT tools, BioLife’s recent share price return has been slightly negative and its 1 year total shareholder return is modestly underwater, suggesting...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLFS":"BioLife Solutions Inc.","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4198":"医疗保健用品","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4121":"生命科学工具和服务"},"translate_title":"BioLife Solutions(BLFS)在第三季度强劲表现、指导上调和新生物保存中心开业后估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLFS":1.5},"content_text":"BioLife Solutions (BLFS) has given investors plenty to chew on after Q3, with an earnings beat, stronger revenue guidance for its cell processing platform, and a new biopreservation center opening in Bothell. See our latest analysis for BioLife Solutions. Even with the upbeat Q3 and the new biopreservation center signaling a long runway for its CGT tools, BioLife’s recent share price return has been slightly negative and its 1 year total shareholder return is modestly underwater, suggesting near term caution but still reflecting a solid 3 year total shareholder return that points to longer term momentum. If BioLife’s pivot into higher growth bioproduction tools has your attention, it could be a good time to scan other innovative healthcare stocks that might be riding similar structural trends. With revenue and earnings momentum building, shares still sitting below analyst targets and a sizable intrinsic discount, investors now face the real question: is BioLife quietly undervalued, or is the market already baking in that growth? AdvertisementMost Popular Narrative: 18.7% Undervalued Compared with the last close at $25.46, the most popular narrative points to a higher fair value, framing BioLife as a long term growth asset rather than a short term trade.  Ongoing customer adoption of multiple integrated products (cross-selling), with evidence of key accounts trialing and potentially implementing new technologies (e.g., CT-5 automated fill, CryoCase), is expected to significantly boost average revenue per dose and improve customer stickiness, supporting both top-line growth and higher net margins over time.  Read the complete narrative. Curious how this cross selling story turns into a higher fair value? The narrative leans on rapid revenue expansion, a margin flip to profitability, and a future earnings multiple more commonly reserved for category leaders. Want to see exactly which growth and margin assumptions power that target? Result: Fair Value of $31.30 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, heavy reliance on a concentrated cell therapy customer base and persistent margin pressure from product mix shifts could quickly challenge this bullish valuation story. Find out about the key risks to this BioLife Solutions narrative. Another Lens on Valuation Analysts see BioLife as roughly 18.7% undervalued at $31.30, but our SWS DCF model is far more generous, putting fair value near $49.97, almost double today’s $25.46 price. Is the market deeply mispricing long term cash flows, or are these forecasts too rosy? Look into how the SWS DCF model arrives at its fair value. BLFS Discounted Cash Flow as at Dec 2025 Build Your Own BioLife Solutions Narrative If you see the story unfolding differently, or want to stress test the assumptions yourself, you can build a fresh narrative in minutes: Do it your way. A great starting point for your BioLife Solutions research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? Before you move on, give yourself an edge by scanning a few targeted stock ideas on Simply Wall St, you will not want to miss these.  Capture early stage potential by checking out these 3573 penny stocks with strong financials that pair tiny price tags with surprisingly solid fundamentals. Explore structural tech shifts by reviewing these 26 AI penny stocks involved in productivity, automation, and next generation software. Seek income and stability through these 15 dividend stocks with yields > 3% that aim to keep paying you while markets stay unpredictable.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BioLife Solutions might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589805638","isCrawlerRequest":true}